Insider Selling: Beigene, Ltd. (NASDAQ:ONC) Insider Sells $2,073,808.68 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 8,146 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the transaction, the insider now directly owns 5,240,882 shares of the company’s stock, valued at $1,334,223,739.56. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Beigene Trading Down 3.9 %

ONC stock opened at $247.07 on Friday. The company has a market capitalization of $24.18 billion, a PE ratio of -29.98, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. As a group, analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on ONC shares. Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and upped their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Macquarie upped their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.